David Aviezer has over 20 years of experience in senior biotechnology executive management, advancing products from early-stage research up to their approval by FDA and into commercialization. From 2002 through 2014 he served as President and Chief Executive Officer of Protalix BioTherapeutics, leading it to public listing on the New York Stock Exchange and to receiving FDA approval of its drug for Gauchers disease, a rare genetic disorder. Prof. Aviezer has hands on experience in creating strategic partnerships and research agreements as well as raising capital in the private and public markets. Before joining Protalix, Prof. Aviezer served as General Manager of ProChon Biotech/CTI, a biotechnology company focused on rare growth disorders. Prior to that, he was a visiting scientist at the Medical Research Division of Cyanamid -Wyeth, now Pfizer, in Pearl River, New York. He holds a PhD in Molecular Biology and Biochemistry from the Weizmann Institute of Science and an MBA from the Bar-Ilan University Business School.

Ran Nussbaum is a managing partner and co-founder of Pontifax. The fund runs more than 50 portfolio companies around the Globe. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. In the past Ran served on Kite pharma BOD (sold to Gilead), cCAM Therapeutics (sold to Merck), and ArQule (sold to Merck), and Prevail Therapeutics (sold to Lilly). He also chaired Ocon Medical, Nasvax, Spearhead, and Biomedix. Currently, Ran sits on many of Pontifax’s portfolio companies including Eloxx Therapeutics (ELOX), and UroGen (URGN). Ran also serves as Keros Therapeutics (KROS) chairman of the board.

Ohad Hammer is a Partner at Pontifax, where he is focused on scouting and project evaluation. He also serves on the board of several of Pontifax’s portfolio companies including AgomAb, Step Pharma and Adcendo. Ohad obtained his MSc in Biology from Tel-Aviv University.

John Doux is a board certified dermatologist and a fellow of the American Academy of Dermatology. He currently serves as a board director for Lutris Pharma; he served previously as board chair of ValenzaBio (acquired by ACELYRIN) and as a board director of Ceptaris Therapeutics (acquired by Actelion Pharmaceuticals) and Palvella Therapeutics. He received his B.S. and M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow in the laboratory of Dr. David Woodley, and completed his training at Brigham and Women’s Hospital and Stanford Medical Center. He subsequently earned an M.B.A. at the Wharton School of Business, where he was a Palmer Scholar. He has been an analyst at Palo Alto Investors since 2004. He was also a co-founder and prior board member of the Dermatology Summit and Dermatology Innovation Forum.